Eagle Genomics innovates at the intersection of biology, data sciences and bioinformatics to develop technical solutions and enterprise information architecture for the microbiomics and genomics era. . . Eagle’s knowledge discovery platform, the e[automateddatascientist], uses machine learning to transform raw data into actionable insights that drive scientific decision making, enabling companies to make more credible scientific claims, enhancing R&D processes and brand perception. . . Eagle’s smart data management solutions and unique expertise gives access to insight that enables quick assessment of product potential, mitigates risks and reduces time to market at many sciences companies across industries including pharmaceutical, biotechnology, crop science, personal hygiene and animal health.
The Earlham Institute (EI) is a research institute applying advanced genomics and computational approaches to aid our understanding of complex biological systems and their interaction with the environment.
Established in 2009 and located on the Norwich Research Park, EI is strategically funded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).
The Earlham Institute (EI) uses expertise in genomics, bioinformatics and molecular biology to answer complex biological questions and improve plant and animal health, and tackle global issues of food security, climate change, conservation and human wellbeing.
EI is home to state-of-the-art laboratories, specialist equipment and facilities enabling genomics and bioinformatics research, including one of the largest supercomputing facilities for life science research in Europe.
Our technology platforms include:
• Genomics and Single-Cell Analysis facility that provides scalable infrastructure for high-throughput DNA/RNA analysis of biological systems.
• BIO Foundry facility that provides services for high-throughput, nanoscale DNA-assembly, low-cost sequence validation of synthetic constructs and microfermentation.
• High-Performance Computing platform that provides access to high-throughput computing clusters and data management support.
• State-of-the-art training facility for bioinformatics and genomics with expert-led courses.
EI has established collaborative projects worldwide. We are involved in collaborative R&D projects with industry through consultancy, contract research, and grant funding.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.. EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:. •
EIP is an innovative Intellectual Property law firm advising on all areas of IP. EIP has more than 60 professional staff practising from its four UK offices in Bath, Cardiff, Leeds and London, its US office in Denver and its German office in Dusseldorf. EIP Life is our life sciences and medical devices team which has a wealth of technical knowledge and experience in dealing with the biotechnology and health sectors, for start-ups and major multinationals.
eLabNext is your partner in lab digitization. Their centralized Digital Lab Platform enables scientists to optimize laboratory processes and accelerate research discoveries. Maximize capabilities by integrating free add-ons from Marketplace or develop your own with eLab APIs & SDKs. Their team of friendly experts are always ready to assist you and your team. eLabNext is a brand of Bio-ITech BV, part of Eppendorf Group.
Watch their video here:
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.
Switzerland is one of the strongest biotech / pharma countries in Europe with global pharma, mature biotech and innovative start-ups, supported by world class research. The Embassy of Switzerland facilitates contacts to Swiss clusters for anyone interested in business or research partnerships.
The mission of EMBL-EBI is to: provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress; contribute to the advancement of biology through basic investigator-driven research in bioinformatics; provide advanced bioinformatics training to scientists at all levels; and help disseminate cutting-edge technologies to industry. . The research and service activities of EMBL-EBI span the entire spectrum of life science and remain at the cutting edge of the computational sciences. All our major data resources are the products of international collaborations. We work with other data providers to ensure that our data repositories, and those of our collaborators, are comprehensive and up to date. We also actively participate in international efforts to develop data standards.. . The EMBL-EBI Industry Programme engages our industrial users with the latest bioinformatics research, service development, standards activities, pre-competitive opportunities and training (www.ebi.ac.uk/industry).